Pharmaceuticals
Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers
Published multicenter study found higher complete wound closure rates and faster healing with Symphony plus standard of care AUCKLAND, New Zealand, Oct. 5, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced positive results from a prospec...
AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide * AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) * Following submission of the Ph...
Celaid Therapeutics Completes Second Close of Series B Financing Round
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO: Nobuyuki Arakawa; "Celaid") today announced the complet...
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collab...
SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026
MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ...
Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy
* First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. * Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal utrophin expression,...
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...
/DISREGARD RELEASE: Jiangsu Vcare/
We are advised by Jiangsu Vcare that journalists and other readers should disregard the news release, Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA, issued 04-Jan-2024 over PR Newswire. ...
Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–Oc...
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
* Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) * New research across clinical trial endpoints, biomarkers, diagnostic t...
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other potential programs leveraging Abogen's RNA proprietary platform SUZHOU, China, Oct. 2, 2026 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the ...
Bambusa Therapeutics Initiates Subcutaneous Dosing of BBT001 in Atopic Dermatitis, Following Compelling Intravenous Proof-of-Concept Data
First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration subcutaneous formulation designed to combine BBT001's emerging profile of rapid, deep and durable clinical activity with convenient administration a...
Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald
Suvoda's latest platform release creates a global experience across study data, patient engagement, scheduling, payments, and clinical trial operations
CONSHOHOCKEN, Pa., Sept. 30, 2026 /PRNewswire/ -- Suvoda
Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month
* Piramal and NP2 are set to complete the drug development phase of the generic cancer drug cyclophosphamide this October. * The development and manufacturing activities are being conducted at Piramal's dedicated sterile injectable facility in Lexington, Kentucky. * This partnership addresse...
Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC
First clinical program built on Phrontline's DLP1 branched dual-payload linker platform HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), today announced that the f...
The 94th CMEF, the World's Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24
BEIJING, Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Hea...
Yuyu Pharma Brings Ari's Purrfect to Amazon Accelerate 2026
Korean pharmaceutical company explores Amazon AI and seller tools to grow its U.S. feline-health brand SEOUL, South Korea, Sept. 30, 2026 /PRNewswire/ -- Robert Wonsang Yu, CEO of Yuyu Pharma (KRX: 000220), attended Amazon Accelerate 2026 in Seattle from September 22 to 24 to explore how Amazon'...
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical
Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China
BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical
Week's Top Stories
Most Reposted
BoomerangFX Launches ChatGPT AI Search Advertising for Aesthetic, Wellness and Private-Pay Healthcare Practices, Powered by AUVIA™ AI Clinic Co-Pilot
[Picked up by 1316 media titles]
2026-11-17 23:03Manulife announces Subordinated Debenture issue
[Picked up by 1206 media titles]
2026-11-17 06:45The NYSE Welcomes vVARDIS as a Publicly Listed Company
[Picked up by 1176 media titles]
2026-11-14 13:23Sunbit to Enter Personal Loans in 2027 Along Its Growth Journey: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-18 21:55Cision MCP Brings Consumer Intelligence into Everyday Workflows
[Picked up by 1116 media titles]
2026-11-19 23:00